Relay Therapeutics, Inc. Operating Lease Liability
Relay Therapeutics, Inc. (RLAY) had Operating Lease Liability of $24.42 million as of 2020-12-31, per its 10-K filed 2021-03-25.
Discontinued › Balance Sheet › Liabilities
us-gaap:OperatingLeaseLiability · last filed 2021-03-25
- 2020-12-31: Operating Lease, Liability $24.42M.
- 2019-12-31: Operating Lease, Liability $24.83M.
| Period end | Operating Lease, Liability |
|---|---|
| 2020-12-31 | $24.42M 10-K · filed 2021-03-25 |
| 2019-12-31 | $24.83M 10-K · filed 2021-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |